Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
Novartis faces investor scrutiny after two key drug trials failed, raising concerns about its M&A strategy and R&D pipeline. The company's recent $12B Avidity buyout is under question, with analysts cutting sales estimates for del-desiran. Novartis' board is criticized for not properly overseeing deals, while CEO Vasant Narasimhan's leadership is praised. The setbacks may impact Novartis' growth prospects post-2030, as key drugs face patent expirations.
How this was made
The 30-second read
Why it matters
The combined trial setbacks and acquisition impairments raise doubts about Novartis' ability to replace revenue from expiring patents, likely prompting a re‑rating of its long‑term growth forecasts.
Market read
The trial failures and M&A scrutiny are material for Novartis and could influence broader pharma valuations.
What to watch
Potential upside from the successful remibrutinib readout and upcoming radiopharmaceutical growth could offset short‑term pain.
Background
Novartis' recent M&A strategy has come under investor pressure after a $12 bn Avidity buyout and a $2.9 bn MorphoSys acquisition, both now facing impairment concerns.
Ticker impact
Novartis reported Phase 3 failures for pelacarsen and del-desiran, and a mixed result for remibrutinib, raising concerns over its pipeline and recent M&A deals.
downward pressure over the next weeks
Phase 3 failures are material for a large pharma; combined with recent acquisition impairments, investors may reassess growth outlook.
Market effects
Biotech and pharma peers may see heightened scrutiny on recent M&A activity and pipeline risk.
European pharma stocks could face broader valuation pressure.
Large‑cap pharma investors worldwide may adjust exposure to pipeline‑driven companies.
Counterpoint
If the remibrutinib data drives optimism, the market may overreact to the failures, presenting a buying opportunity.
Key entities
- companyNovartis
Swiss pharmaceutical giant, ticker NVS.
- companyAvidity Biosciences
Acquired by Novartis for del‑desiran and related assets.
- companyMorphoSys
Biotech acquired by Novartis in 2024.
